Richard Moss

List of Publications by Citations

131 papers	12,654 citations	54 h-index	112 g-index
153 ext. papers	14,455 ext. citations	7.1 avg, IF	5.89 L-index

#	Paper	IF	Citations
131	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *New England Journal of Medicine*, **2011**, 365, 1663-72	59.2	1465
130	Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *New England Journal of Medicine*, **2015**, 373, 220-31	59.2	910
129	Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. *New England Journal of Medicine*, **2010**, 363, 1991-2003	59.2	598
128	Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. *Clinical Infectious Diseases*, **2003**, 37 Suppl 3, S225-64	11.6	506
127	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clinical and Experimental Allergy*, **2013**, 43, 850-73	4.1	483
126	Late pulmonary sequelae of bronchopulmonary dysplasia. *New England Journal of Medicine*, **1990**, 323, 1793-9	59.2	454
125	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. *Thorax*, **2012**, 67, 12-8	7.3	408
124	Fungi and allergic lower respiratory tract diseases. *Journal of Allergy and Clinical Immunology*, **2012**, 129, 280-91; quiz 292-3	11.5	316
123	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. *Lancet Respiratory Medicine,the*, **2014**, 2, 527-38	35.1	309
122	Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. *Chest*, **2004**, 125, 509-21	5.3	309
121	Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 841-9	10.2	257
120	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Respiratory Medicine,the*, **2014**, 2, 539-47	35.1	242
119	A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. *Human Gene Therapy*, **2002**, 13, 1349-59	4.8	213
118	Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. *Human Gene Therapy*, **2007**, 18, 726-32	4.8	202
117	High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 4628-33	11.5	196
116	A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. *Human Gene Therapy*, **2001**, 12, 1907-16	4.8	196
115	Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. *Lancet, The*, **1998**, 351, 1702-3	40	188

114	Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. *Laryngoscope*, **1999**, 109, 266-74	3.6	170
113	Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. *JAMA Pediatrics*, **2011**, 165, 847-56		162
112	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. *Lancet Respiratory Medicine,the*, **2015**, 3, 524-33	35.1	161
111	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. *Lancet Respiratory Medicine,the*, **2017**, 5, 107-118	35.1	158
110	Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. *Journal of Allergy and Clinical Immunology*, **1986**, 78, 590-600	11.5	151
109	Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. *Chest*, **2002**, 121, 55-63	5.3	141
108	Cow's milk allergy in breast-fed infants: the role of allergen and maternal secretory IgA antibody. *Journal of Allergy and Clinical Immunology*, **1986**, 77, 341-7	11.5	131
107	Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. *Chest*, **2005**, 128, 2316-26	5.3	125
106	Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. *Journal of Pediatrics*, **1988**, 112, 547-54	3.6	123
105	Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. *Journal of Pediatrics*, **1998**, 133, 18-27	3.6	121
104	Osteopenia in adults with cystic fibrosis. *American Journal of Medicine*, **1994**, 96, 27-34	2.4	121
103	Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. *Chest*, **1999**, 115, 364-70	5.3	118
102	Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4335-9	11.5	104
101	Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. *Journal of Pediatrics*, **1999**, 134, 413-21	3.6	102
100	Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. *Clinical and Experimental Immunology*, **2000**, 120, 518-25	6.2	90
99	Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. *Journal of Allergy and Clinical Immunology*, **1984**, 73, 283-90	11.5	88
98	A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. *Human Gene Therapy*, **1998**, 9, 889-909	4.8	85
97	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2013**, 12, 241-8	4.1	84

96	Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. *Chest*, **2005**, 128, 2327-35	5.3	84
95	Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. *Pediatric Pulmonology*, **2007**, 42, 610-23	3.5	79
94	Pulmonary sequelae of bronchopulmonary dysplasia survivors: high-resolution CT findings. *American Journal of Roentgenology*, **2000**, 174, 1323-6	5.4	77
93	Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 5779-83	11.5	75
92	No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. *American Journal of Respiratory Cell and Molecular Biology*, **2007**, 37, 57-66	5.7	75
91	Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. *Journal of Cystic Fibrosis*, **2015**, 14, 219-27	4.1	73
90	Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. *Lancet, The* , **1990**, 335, 1077-8	40	73
89	Allergy to semisynthetic penicillins in cystic fibrosis. *Journal of Pediatrics*, **1984**, 104, 460-6	3.6	73
88	Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 588-93	10.2	71
87	Administration of aerosolized antibiotics in cystic fibrosis patients. *Chest*, **2001**, 120, 107S-113S	5.3	71
86	A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. *Human Molecular Genetics*, **1998**, 7, 729-35	5.6	71
85	Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). *Clinical and Experimental Immunology*, **1996**, 106, 374-88	6.2	71
84	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. *Journal of Cystic Fibrosis* , **2012**, 11, 539-49	4.1	68
83	Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. *Pediatric Pulmonology*, **2004**, 38, 396-405	3.5	66
82	Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. *Medical Mycology*, **2005**, 43 Suppl 1, S203-6	3.9	63
81	Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 627-34	10.2	62
80	Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. *Journal of Pediatrics*, **2001**, 138, 553-9	3.6	62
79	Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. *PLoS ONE*, **2015**, 10, e0134692	3.7	62

78	Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. *Current Opinion in Pulmonary Medicine*, **2010**, 16, 598-603	3	61
77	Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. *American Journal of Respiratory and Critical Care Medicine*, **1996**, 153, 1914-7	10.2	54
76	Suppression of the late cutaneous response by immunotherapy. *Journal of Allergy and Clinical Immunology*, **1989**, 83, 101-9	11.5	53
75	Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. *European Respiratory Journal*, **2014**, 43, 1487-500	13.6	52
74	Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. *Pediatric Pulmonology*, **2005**, 39, 209-18	3.5	51
73	Earth Mover's Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations. *PLoS ONE*, **2016**, 11, e0151859	3.7	50
72	Constipation and meconium ileus equivalent in patients with cystic fibrosis. *Pediatrics*, **1986**, 78, 473-9	7.4	48
71	Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. *Journal of Pediatrics*, **1992**, 120, 16-21	3.6	47
70	Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. *Journal of Allergy and Clinical Immunology*, **1991**, 87, 78-88	11.5	46
69	Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. *Journal of Child Neurology*, **2010**, 25, 815-21	2.5	45
68	The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis. *Journal of Allergy and Clinical Immunology*, **2016**, 137, 436-443.e9	11.5	44
67	Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. *Pediatric Pulmonology*, **2010**, 45, 934-44	3.5	43
66	Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. *Pediatric Research*, **1986**, 20, 453-9	3.2	42
65	Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2015**, 14, 474-81	4.1	41
64	Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. *PLoS ONE*, **2013**, 8, e66955	3.7	40
63	A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. *PLoS ONE*, **2014**, 9, e88564	3.7	40
62	Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. *Journal of Allergy and Clinical Immunology*, **1987**, 79, 387-98	11.5	38
61	Allergic Bronchopulmonary Aspergillosis. *Journal of Fungi (Basel, Switzerland)*, **2016**, 2,	5.6	38

60	Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. *The American Review of Respiratory Disease*, **1980**, 121, 23-9		38
59	Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. *Journal of Cystic Fibrosis*, **2012**, 11, 502-10	4.1	37
58	Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. *Pancreas*, **2006**, 32, 258-63	2.6	36
57	Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. *Clinical and Molecular Allergy*, **2006**, 4, 11	3.7	36
56	Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. *European Respiratory Journal*, **2016**, 47, 177-85	13.6	35
55	Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. *Pediatric Pulmonology*, **1990**, 9, 7-18	3.5	34
54	125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. *Journal of Pediatrics*, **1981**, 99, 215-22	3.6	33
53	Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. *Current Opinion in Pediatrics*, **2018**, 30, 372-377	3.2	32
52	Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. *Journal of Pediatrics*, **2013**, 162, 676-80	3.6	32
51	Diagnostic testing by CFTR gene mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum. *Journal of Molecular Diagnostics*, **2005**, 7, 289-99	5.1	32
50	Two novel mutations in a cystic fibrosis patient of Chinese origin. *Human Genetics*, **1999**, 104, 511-5	6.3	29
49	Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2013**, 26, 69-75	3.8	28
48	Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. *Journal of Pediatrics*, **2011**, 159, 819-824.e1	3.6	27
47	The myriad challenges of respiratory fungal infection in cystic fibrosis. *Pediatric Pulmonology*, **2018**, 53, S75-S85	3.5	26
46	Fungi in cystic fibrosis and non-cystic fibrosis bronchiectasis. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 207-16	3.9	26
45	Fully automated system for three-dimensional bronchial morphology analysis using volumetric multidetector computed tomography of the chest. *Journal of Digital Imaging*, **2006**, 19, 132-9	5.3	26
44	Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. *Journal of Clinical Investigation*, **1989**, 84, 1794-804	15.9	26
43	Comprehensive mutation screening in a cystic fibrosis center. *Pediatrics*, **2001**, 107, 280-6	7.4	25

42	Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. *Pediatric Research*, **1987**, 22, 708-13	3.2	25
41	Anti-arthropod saliva antibodies among residents of a community at high risk for Lyme disease in California. *American Journal of Tropical Medicine and Hygiene*, **1999**, 61, 850-9	3.2	25
40	Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. *Journal of Gene Medicine*, **1999**, 1, 13-21	3.5	25
39	Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. *Pediatric Pulmonology*, **2009**, 44, 1107-17	3.5	24
38	Alternative pharmacotherapies for steroid-dependent asthma. *Chest*, **1995**, 107, 817-25	5.3	23
37	Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. *Chest*, **1987**, 91, 522-6	5.3	22
36	Reproducibility of skin prick testing with allergen extracts from different manufacturers. *Allergy: European Journal of Allergy and Clinical Immunology*, **1988**, 43, 458-63	9.3	21
35	The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. *Annals of the New York Academy of Sciences*, **2012**, 1272, 49-57	6.5	20
34	IgE antibodies in tick bite-induced anaphylaxis. *Journal of Allergy and Clinical Immunology*, **1991**, 88, 968-70	11.5	18
33	Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. *Clinical and Experimental Immunology*, **2004**, 135, 358-60	6.2	17
32	Advances against aspergillosis. *Clinical Infectious Diseases*, **2003**, 37 Suppl 3, S155-6	11.6	17
31	Interobserver variance in clinical scoring for cystic fibrosis. *Chest*, **1987**, 91, 878-82	5.3	17
30	Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. *Journal of Allergy and Clinical Immunology*, **1985**, 76, 172-6	11.5	16
29	Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function. *Journal of Cystic Fibrosis*, **2019**, 18, 64-70	4.1	15
28	Activation of eosinophils in the airways of lung transplantation patients. *Chest*, **1997**, 112, 1180-3	5.3	15
27	Supraventricular tachycardia in patients with cystic fibrosis. *Chest*, **1986**, 90, 239-42	5.3	15
26	Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. *Journal of Cystic Fibrosis*, **2009**, 8, 1-8	4.1	14
25	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2180-4	5.9	13

24	Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm. *Mycopathologia*, **2018**, 183, 263-272	2.9	13
23	Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas. *Mycopathologia*, **2017**, 182, 315-318	2.9	10
22	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. *Journal of Cystic Fibrosis*, **2018**, 17, 503-510	4.1	10
21	Recent advances in cystic fibrosis. *Current Opinion in Pediatrics*, **2015**, 27, 317-24	3.2	8
20	Critique of trials in allergic bronchopulmonary aspergillosis and fungal allergy. *Medical Mycology*, **2006**, 44, S269-S272	3.9	8
19	Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. *Pediatric Pulmonology*, **2020**, 55, 929-938	3.5	7
18	The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements. *PLoS ONE*, **2017**, 12, e0175486	3.7	7
17	Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1195-1196	11.5	6
16	Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. *Journal of Allergy and Clinical Immunology*, **1987**, 80, 798-802	11.5	6
15	Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 1909-1930.e4	5.4	5
14	Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. *Scientific Reports*, **2018**, 8, 16233	4.9	5
13	Novel Cystic Fibrosis mutation L1093P: functional analysis and possible Native American origin. *Human Mutation*, **2000**, 15, 208	4.7	4
12	Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. *Pulmonary Therapy*, **2020**, 6, 303-313	3	4
11	Current treatment options for invasive aspergillosis. *Drugs of Today*, **2013**, 49, 213-26	2.5	3
10	Management of allergic aspergillosis. *Current Allergy and Asthma Reports*, **2008**, 8, 433-439	5.6	3
9	Management of allergic aspergillosis. *Current Fungal Infection Reports*, **2008**, 2, 87-93	1.4	3
8	Manifestations of pulmonary aspergillosis in pediatrics. *Current Opinion in Pediatrics*, **2020**, 32, 389-394	3.2	3
7	Immunoglobulin E antibodies in young children with possible allergic symptoms. *Journal of Pediatrics*, **1987**, 110, 738-40	3.6	2

6	Susceptibility of Candida albicans from Cystic Fibrosis Patients. *Mycopathologia*, **2017**, 182, 863-867	2.9	1
5	Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis. *American Journal of Medical Genetics, Part A*, **2005**, 133A, 103-5	2.5	1
4	124 Grass pollen immunotherapy, clinical and immunologic effects in a double-blind placebo-controlled study. *Journal of Allergy and Clinical Immunology*, **1983**, 71, 119	11.5	1
3	Mucosal humoral immunity in cystic fibrosis - a tangled web of failed proteostasis, infection and adaptive immunity. *EBioMedicine*, **2020**, 60, 103035	8.8	0
2	Vocal Cord Dysfunction Syndrome and Steroid-Dependent Asthmatics. *Chest*, **1995**, 108, 1772-1773	5.3	
1	Clinical protocol: AAV-CFTR for the treatment of chronic sinusitis in CF patients.. *Clinical Pharmacology and Therapeutics*, **1996**, 59, 174-174	6.1	